The "newer" progestogens and postmenopausal hormone therapy (HRT)

Area of Science:

• Reproductive endocrinology
• Menopause management
• Pharmacology of hormone therapy

Background:

• Global decline in hormone therapy (HT) use post-2002 WHI and MWS studies.
• Re-evaluation of HT and specific progestogens due to side effect concerns.
• Need for progestogens that balance endometrial protection with metabolic and hemostatic neutrality.

Purpose of the Study:

• To review the actions of three newer progestogens: dienogest, drospirenone, and nomegestrol acetate.
• To assess their efficacy and safety in combination with estradiol for hormone therapy.
• To guide renewed interest in HT for menopause management.

Main Methods:

• Literature review of scientific publications on dienogest, drospirenone, and nomegestrol acetate.
• Analysis of progestogen effects on endometrial proliferation.
• Evaluation of impact on carbohydrate/lipid metabolism and hemostasis.
• Assessment of combined effects with estradiol.

Main Results:

• Dienogest, drospirenone, and nomegestrol acetate demonstrate varying profiles in endometrial control.
• These progestogens show differential effects on metabolic parameters and coagulation factors.
• Combined use with estradiol requires careful consideration of individual progestogen actions.

Conclusions:

• Newer progestogens offer potential alternatives in hormone therapy for menopause.
• Careful selection based on endometrial, metabolic, and hemostatic profiles is crucial.
• Further research can optimize HT strategies for women's health.